{"id":"NCT00982007","sponsor":"American Regent, Inc.","briefTitle":"Efficacy and Safety of Intravenous Ferric Carboxymaltose (FCM) in Patients With Iron Deficiency Anemia (IDA)","officialTitle":"A Multi-center, Randomized, Active Controlled Study to Investigate the Efficacy and Safety of Intravenous Ferric Carboxymaltose (FCM) in Patients With Iron Deficiency Anemia (IDA)","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2009-09","primaryCompletion":"2011-03","completion":"2011-08","firstPosted":"2009-09-22","resultsPosted":"2013-10-18","lastUpdate":"2018-02-20"},"enrollment":997,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Iron Deficiency Anemia"],"interventions":[{"type":"DRUG","name":"Ferric Carboxymaltose (FCM)","otherNames":[]},{"type":"DRUG","name":"Ferrous Sulfate Tablets","otherNames":[]},{"type":"DRUG","name":"IV Iron (standard of care)","otherNames":[]},{"type":"DRUG","name":"Ferric Carboxymaltose (FCM)","otherNames":[]}],"arms":[{"label":"Cohort 1 (Group A) - Ferric Carboxymaltose (FCM)","type":"EXPERIMENTAL"},{"label":"Cohort 1 (Group B) - Ferrous Sulfate","type":"ACTIVE_COMPARATOR"},{"label":"Cohort 2 (Group D) - IV Iron (standard of care)","type":"ACTIVE_COMPARATOR"},{"label":"Cohort 2 (Group C) - Ferric Carboxymaltose (FCM)","type":"EXPERIMENTAL"}],"summary":"The main objective of this study is to demonstrate the efficacy and safety of an investigational intravenous (IV) iron, ferric carboxymaltose (FCM), compared to oral iron in subjects who have iron deficiency anemia (IDA) and have shown an unsatisfactory response to oral iron.","primaryOutcome":{"measure":"Mean Increase From Baseline to the Highest Observed Hemoglobin Value Between Baseline and Day 35 or Time of Intervention for Patients Taking FCM as Compared to That for Patients Taking Ferrous Sulfate.","timeFrame":"Day 35","effectByArm":[{"arm":"Cohort 1 (Group A) - Ferric Carboxymaltose (FCM)","deltaMin":1.57,"sd":1.194},{"arm":"Cohort 1 (Group B) - Ferrous Sulfate","deltaMin":0.8,"sd":0.799},{"arm":"Cohort 2 (Group C) - Ferric Carboxymaltose (FCM)","deltaMin":2.9,"sd":1.64},{"arm":"Cohort 2 (Group D) - IV Iron (Standard of Care)","deltaMin":2.16,"sd":1.252}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":5,"exclusionCount":13},"locations":{"siteCount":1,"countries":["United States"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":8,"n":246},"commonTop":["Nausea","Hypophosphatemia"]}}